These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33872498)

  • 1. Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2.
    Dai W; Jochmans D; Xie H; Yang H; Li J; Su H; Chang D; Wang J; Peng J; Zhu L; Nian Y; Hilgenfeld R; Jiang H; Chen K; Zhang L; Xu Y; Neyts J; Liu H
    J Med Chem; 2022 Feb; 65(4):2794-2808. PubMed ID: 33872498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL
    Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR
    J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.
    Konno S; Kobayashi K; Senda M; Funai Y; Seki Y; Tamai I; Schäkel L; Sakata K; Pillaiyar T; Taguchi A; Taniguchi A; Gütschow M; Müller CE; Takeuchi K; Hirohama M; Kawaguchi A; Kojima M; Senda T; Shirasaka Y; Kamitani W; Hayashi Y
    J Med Chem; 2022 Feb; 65(4):2926-2939. PubMed ID: 34313428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
    Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA
    J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
    Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM
    J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of SARS-CoV-2 3CL
    Wang Y; Xu B; Ma S; Wang H; Shang L; Zhu C; Ye S
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
    Kitamura N; Sacco MD; Ma C; Hu Y; Townsend JA; Meng X; Zhang F; Zhang X; Ba M; Szeto T; Kukuljac A; Marty MT; Schultz D; Cherry S; Xiang Y; Chen Y; Wang J
    J Med Chem; 2022 Feb; 65(4):2848-2865. PubMed ID: 33891389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrocyclic Azapeptide Nitriles: Structure-Based Discovery of Potent SARS-CoV-2 Main Protease Inhibitors as Antiviral Drugs.
    Breidenbach J; Voget R; Si Y; Hingst A; Claff T; Sylvester K; Wolf V; Krasniqi V; Useini A; Sträter N; Ogura Y; Kawaguchi A; Müller CE; Gütschow M
    J Med Chem; 2024 Jun; 67(11):8757-8790. PubMed ID: 38753594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship study of peptidomimetic aldehydes as enterovirus 71 3C protease inhibitors.
    Zhai Y; Ma Y; Ma F; Nie Q; Ren X; Wang Y; Shang L; Yin Z
    Eur J Med Chem; 2016 Nov; 124():559-573. PubMed ID: 27614190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment.
    Zhang L; Lin D; Kusov Y; Nian Y; Ma Q; Wang J; von Brunn A; Leyssen P; Lanko K; Neyts J; de Wilde A; Snijder EJ; Liu H; Hilgenfeld R
    J Med Chem; 2020 May; 63(9):4562-4578. PubMed ID: 32045235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies.
    Dampalla CS; Rathnayake AD; Perera KD; Jesri AM; Nguyen HN; Miller MJ; Thurman HA; Zheng J; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Kim Y; Groutas WC; Chang KO
    J Med Chem; 2021 Dec; 64(24):17846-17865. PubMed ID: 34865476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease.
    Chaibi FZ; Brier L; Carré P; Landry V; Desmarets L; Tarricone A; Cantrelle FX; Moschidi D; Herledan A; Biela A; Bourgeois F; Ribes C; Ikherbane S; Malessan M; Dubuisson J; Belouzard S; Hanoulle X; Leroux F; Deprez B; Charton J
    Eur J Med Chem; 2024 Oct; 276():116707. PubMed ID: 39068863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
    Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR
    ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of macrocyclic covalent inhibitors for severe acute respiratory syndrome coronavirus 2 3CL protease.
    Tang X; Hou K; Chen X; Fan W; Wu H; Lu C; He GX
    Bioorg Med Chem; 2024 Sep; 111():117846. PubMed ID: 39106653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study.
    Thanigaimalai P; Konno S; Yamamoto T; Koiwai Y; Taguchi A; Takayama K; Yakushiji F; Akaji K; Kiso Y; Kawasaki Y; Chen SE; Naser-Tavakolian A; Schön A; Freire E; Hayashi Y
    Eur J Med Chem; 2013 Jul; 65():436-47. PubMed ID: 23747811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors.
    Paul A; Sarkar A; Saha S; Maji A; Janah P; Kumar Maity T
    Bioorg Med Chem; 2021 Sep; 46():116301. PubMed ID: 34332853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL
    Kumar V; Shin JS; Shie JJ; Ku KB; Kim C; Go YY; Huang KF; Kim M; Liang PH
    Antiviral Res; 2017 May; 141():101-106. PubMed ID: 28216367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological activity evaluation of dihydromyricetin derivatives against SARS-CoV-2-Omicron virus.
    Wu C; Jiang Q; Zhong H; Zhou X; Liu L; Pan T; Liu C; Wang W; Sheng W
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2390909. PubMed ID: 39206852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.
    Lee JY; Kuo CJ; Shin JS; Jung E; Liang PH; Jung YS
    Bioorg Med Chem Lett; 2021 Jun; 42():128067. PubMed ID: 33957246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CL
    Jiang Z; Feng B; Chen L; Nie T; Chen S; Wang L; Liu H; Yu T; Zhang Y; Zheng M; Xu Y; Liu H; Zang Y; Su H; Zhang L; Li J; Zhou Y
    J Med Chem; 2024 Aug; 67(15):12760-12783. PubMed ID: 39072488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.